With Actual Data, Vericel Loses Its Shine
Insights - Vericel Corp (VCEL) cratered on Monday with details from a phase 2b study of its ixmyelocel-T cell therapy for heart failure, presented at the American College … Continue Reading
Read NowInsights
Though Expected, Regeneron’s New Anti-Inflammatory Succeeds in Skin Disorder
Insights - On Friday, the companies announced success in two phase 3 studies of the IL-4/IL-13 antibody in AD, and now plan to file for approval later this year with the FDA.
Read Now
Acadia Passes Last Hurdle Before FDA Approval Decision
Insights - Acadia Pharmaceuticals' (ACAD) pimavanserin received a positive opinion from a panel of outside experts to the U.S. FDA on Tuesday, a final step before the regulatory body decides on the drug's approval in Parkinson's Disease Psychosis this May.
Read Now
Portola Stock Bleeds With Latest Drug Study Results
Insights - Portola used a unique study design in an attempt to enrich the trial and improve its odds of success. That might ultimately be betrixaban's undoing.
Read Now
GW Pharma Rips Higher on New Epilepsy Data
Insights - Shares of GW Pharmaceuticals (GWPH) doubled on Monday with the much-anticipated release of positive data from a phase 3 study of Epidiolex, the company’s proprietary formulation of … Continue Reading
Read Now
That Rally! For Now, Optimism is Back
Insights - Biotech had a Super Wednesday after Bernie Sanders’ not-so-super Tuesday.
Premium: Read Now
Chimerix: When Good Is Bad In Biotech
Insights - From a $2 billion valuation to less than $300 million in five months, Chimerix (CMRX) (of Josh Hardy fame) is a standout among biotech stocks, for … Continue Reading
Read Now